Positron

Positron Corporation Announces Attrius® PET System Sale

Retrieved on: 
Friday, November 24, 2023
Molecular imaging, Physician, PET, Hospital, POSC, Positron Corporation, SPECT, Positron, OTC, Medical imaging

Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in Pennsylvania as a new customer utilizing Positron’s Attrius® PET System and services.

Key Points: 
  • Niagara Falls, NY, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in Pennsylvania as a new customer utilizing Positron’s Attrius® PET System and services.
  • Positron is the only company in the industry offering a dedicated PET scanner optimized for nuclear cardiology.
  • Adel Abdullah, President of Positron stated, “We are pleased to be part of our customers evolution from SPECT to cardiac PET imaging.
  • Positron’s Attrius dedicated PET system and services provides nuclear imaging practices the best value through the combination of high technology and  cost-effective imaging solutions.

MaxLinear and Positron Partner to Accelerate Broadband Deployment with Fiber Speeds to the Home

Retrieved on: 
Monday, October 16, 2023
Mobile, Wireless, Technology, Semiconductor, Security, Satellite, Telecommunications, Networks, Hardware, Data Management, Consumer Electronics, GAM, Digital divide, SISO, POF, QOS, MXL, Network, G.hn, Fed, CATV, MDU Wi-Fi, MIMO, Power, Quality of service, RPF, Environment, Gigabit Ethernet, Home, Wi-Fi, ITU, Internet service provider, Medical imaging, Positron, MaxLinear

The Positron GAM solutions extend fiber and fixed-wireless access Gigabit services to legacy properties over the existing coax or twisted pair wiring infrastructures.

Key Points: 
  • The Positron GAM solutions extend fiber and fixed-wireless access Gigabit services to legacy properties over the existing coax or twisted pair wiring infrastructures.
  • MaxLinear and Positron will showcase these solutions at Network X in Paris, France, October 24 – 26.
  • View the full release here: https://www.businesswire.com/news/home/20231016961564/en/
    MaxLinear and Positron Partner to Accelerate Broadband Deployment with Fiber Speeds to the Home (Graphic: Business Wire)
    The versatility of the G.hn as a Gigabit access technology standard provides subscribers with ultra-fast and reliable network connectivity.
  • “Connectivity convergence is becoming increasingly important as consumers demand reliable access at Gigabit speeds,” said Will Torgerson, Vice President, Broadband Group for MaxLinear.

Positron Corporation Announces Attrius® PET System Sale

Retrieved on: 
Wednesday, October 4, 2023
POSC, Positron Corporation, Positron, PET, Eastman Kodak Co. v. Image Technical Services, Inc., SPECT, Hospital, Physician, Molecular imaging, OTC, Medical imaging

Niagara Falls, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in California as a new customer utilizing Positron’s Attrius® PET System and services.

Key Points: 
  • Niagara Falls, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET imaging systems and clinical services, is pleased to welcome a prominent cardiovascular practice in California as a new customer utilizing Positron’s Attrius® PET System and services.
  • Positron is the only company in the industry offering a dedicated PET scanner optimized for nuclear cardiology.
  • This transaction is the introduction of the Company’s PET Lease to Own & Services Program, where customers pay one price for a complete package which includes an Attrius PET System and the full scope Clinical & Technical Services.
  • This Program has zero upfront capex expense which provides a most viable operational model for nuclear imaging PET practices seeking the PET modality.

Positron Corporation Announces Start of Clinical Study of Affinity PET-CT Device

Retrieved on: 
Friday, September 8, 2023
Ochsner Health System, Institutional review board, Federal Food, Drug, and Cosmetic Act, Investigational device exemption, POSC, International Committee for the Nanking Safety Zone, Molecular imaging, Positron Corporation, Trial of the century, Register, Documentation, Patient, Physician, OTC, Affinity, FDA, Medical imaging, Positron

Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity™ PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA.

Key Points: 
  • Niagara Falls, NY, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company will begin its clinical study of its Affinity™ PET-CT imaging device with Ochsner Clinic Foundation in New Orleans, LA.
  • The objective of the clinical study is to obtain key data that will represent the performance and efficacy of Positron’s new state-of-the-art PET-CT imaging device.
  • The initial phase of the clinical study will consist of phantom testing and subsequent imaging of human patients once Positron receives its Investigational Device Exemption from the FDA.
  • In parallel with the clinical study Positron will submit its 510k and Registration to the FDA for clearance to market and sell the Affinity PET-CT.

Positron Corporation Orders Six Attrius® PET Systems and Components from Neusoft Positron Medical Systems

Retrieved on: 
Monday, July 31, 2023
POSC, Positron Corporation, Positron, PET, Eastman Kodak Co. v. Image Technical Services, Inc., PET-CT, Hospital, Patient, Physician, Molecular imaging, OTC, Growth, Medical imaging

Niagara Falls, NY, July 31, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company that manufactures, sells and services PET imaging systems and clinical services, is pleased to announce that in combination with its new Business Cooperative Partnership with Shenyang Intelligent Neuclear Medical Technology Co, a wholly owned subsidiary of Neusoft Medical Systems, Positron has agreed on terms to purchase the current inventory from the Company’s PET Joint Venture partner, Neusoft Positron Medical Systems.

Key Points: 
  • Niagara Falls, NY, July 31, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company that manufactures, sells and services PET imaging systems and clinical services, is pleased to announce that in combination with its new Business Cooperative Partnership with Shenyang Intelligent Neuclear Medical Technology Co, a wholly owned subsidiary of Neusoft Medical Systems, Positron has agreed on terms to purchase the current inventory from the Company’s PET Joint Venture partner, Neusoft Positron Medical Systems.
  • Positron will acquire six (6) Attrius PET systems and all Attrius PET system components held in inventory, with an estimated value of $6 million dollars.
  • The Attrius components inventory provides a full spectrum of parts which will service Attrius PET customers over the next decade.
  • Positron has identified multiple nuclear cardiology practices seeking to purchase Attrius  dedicated PET only systems with several sales proposals currently in the process of acceptance.

Positron Corporation Enters New Manufacturing & Components Supplier Cooperative with Neusoft Medical Systems Subsidiary for New PET-CT Device

Retrieved on: 
Friday, July 21, 2023
Federal Food, Drug, and Cosmetic Act, Communication, POSC, Classification, Positron Corporation, Atakent (business cooperation center), PET-CT, Engineering, Molecular imaging, OTC, Affinity, FDA, LTD, Medical imaging, Positron, Neusoft

Niagara Falls, NY, July 21, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company has entered an Novation Agreement with Shenyang Intelligent Neuclear Medical Technology Co, LTD (Intelligent Neuclear Medical), a wholly owned subsidiary of Neusoft Medical Systems (Neusoft), that transfers the original Business Cooperation Agreement between Positron and Neusoft Medical Systems (“Neusoft”) to now include Neusoft’s subsidiary, Intelligent Neuclear Medical.

Key Points: 
  • Niagara Falls, NY, July 21, 2023 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company, is pleased to announce that the Company has entered an Novation Agreement with Shenyang Intelligent Neuclear Medical Technology Co, LTD (Intelligent Neuclear Medical), a wholly owned subsidiary of Neusoft Medical Systems (Neusoft), that transfers the original Business Cooperation Agreement between Positron and Neusoft Medical Systems (“Neusoft”) to now include Neusoft’s subsidiary, Intelligent Neuclear Medical.
  • Positron has expanded its role as manufacturer with Intelligent Neuclear Medical designated as the Company’s contracted components supplier.
  • Positron’s classification as the device manufacturer is significant as it will register with the FDA as the applicant  of its FDA 510k submission for Medical Device Clearance for its Affinity PET-CT imaging device.
  • Neusoft formed Intelligent Neuclear Medical as a wholly owned subsidiary to segregate all Neusoft’s current nuclear projects and products, which also includes all nuclear R&D technology initiatives.

Hotel Nikko San Francisco Elevates Broadband Connectivity with Innovative Technology

Retrieved on: 
Thursday, June 29, 2023
Telecom, Positron, Copper, Nikko Hotels, Wi-Fi, IPTV, GAM, Hotel Nikko San Francisco, Mobile phone

TORONTO, June 29, 2023 /PRNewswire-PRWeb/ -- Hotel Nikko San Francisco, a renowned luxury high-rise hotel located at 222 Mason Street, has announced the successful deployment of its high-speed Wi-Fi service. Using a ground-breaking solution from Positron Access Solutions, that combines Wi-Fi and bandwidth to create a less disruptive than fibre installation, by repurposing the existing coax to improve connectivity for all guests and enhance every individual's experience while staying at the 532-room hotel.

Key Points: 
  • Hotel Nikko San Francisco, a renowned luxury high-rise hotel located at 222 Mason Street, has announced the successful deployment of its high-speed Wi-Fi service.
  • TORONTO, June 29, 2023 /PRNewswire-PRWeb/ -- Hotel Nikko San Francisco, a renowned luxury high-rise hotel located at 222 Mason Street, has announced the successful deployment of its high-speed Wi-Fi service.
  • "We were astounded by the remarkable data speed rates we achieved during the proof of concept with Positron," said David Ng, Director of IT at Hotel Nikko San Francisco.
  • Hotel Nikko San Francisco's successful deployment of this cutting-edge technology marks a significant milestone, exemplifying how hotels can overcome connectivity challenges while leveraging their existing infrastructure investment.

Positron Corporation Enters into Agreement with Ochsner Clinic Foundation for Clinical Study of its New “Affinity PET-CT 4D” Device

Retrieved on: 
Wednesday, March 1, 2023
Clinical trial, Cardiology, Clinical, Safety, Certification, International Committee for the Nanking Safety Zone, Affinity, IDE, Molecular imaging, Ochsner Health System, OTC, Institutional review board, FDA, Trial of the century, IRB, PMA, POSC, PET, Federal Food, Drug, and Cosmetic Act, Biomedical Research, Positron Corporation, Medical imaging, Positron

All procedures and participants for the clinical study have been evaluated and approved as required by an independent Institutional Review Board (IRB).

Key Points: 
  • All procedures and participants for the clinical study have been evaluated and approved as required by an independent Institutional Review Board (IRB).
  • Acceptance of the clinical study by the IRB allows Positron to obtain an Investigational Device Exemption (IDE) which is required to collect safety and efficacy data for Positron’s new PET-CT device.
  • The clinical study will be registered in accordance with the requirements of the International Committee of Medical Journal Editors.
  • Positron expects completion of its clinical study and FDA Certification within the next 60 days.

Positron Corporation Announces Plans for Clinical Study of its New “Affinity PET-CT 4D” Nuclear Imaging Device

Retrieved on: 
Tuesday, December 20, 2022
Ochsner Health System, Institutional review board, Cardiology, Record, GCP, Ochsner, Good, Trial of the century, Patient, Nuclear medicine, Molecular imaging, OTC, Certification, FDA, POSC, IRB, Positron Corporation, Biomedical Research, Affinity, Medical imaging, Positron

The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health.

Key Points: 
  • The clinical study is sponsored by Positron and will be conducted by Dr. Robert Bober, Director of Molecular Imaging and Nuclear Cardiology of Ochsner Health.
  • Dr. Bober has furnished a plan for the clinical study to an Institutional Review Board (IRB), which reviews and monitors biomedical research involving human subjects in accordance with FDA regulations.
  • Performing such an extensive clinical study requires a comprehensive investigational plan, patient selection criteria, labeling, and monitoring with records and reports which adhere to Good Clinical Practices (GCP).
  • The study will provide empirical data necessary for proper representation of the system’s image quality, performance, and efficacy with  cardiac PET imaging agents.

Brazilian Connected Trucks Telematics Market Report 2022: The Market is Moderately Fragmented, with 54.7% Concentrated in 5 TSPs - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Technology, Trucking, Transport, Telecommunications, Risk management, Health, Insurance, Transport, Volvo, Growth, Agriculture, Satellite navigation, Volkswagen, Original equipment manufacturer, Research, Iveco, Mercedes-Benz, Safety, Positron, KPI-driven code analysis, Solution, Renewable energy

The "Brazilian Connected Trucks Telematics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brazilian Connected Trucks Telematics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This research service performs a comprehensive analysis of the Brazilian connected trucks telematics market, which includes market growth opportunities and considers industry KPIs and the micro and macroeconomic growth trends.
  • This research will provide meaningful insights for telematics providers (OEMs, TSPs, and start-ups) wishing to explore this growing and competitive market.
  • The Brazilian connected trucks telematics market is showing good indicators for growth.